Oral small molecule compounds that promote the skipping of exon 51 in the DMD gene

被引：0
|
作者：
Naryshkin, N. A. [1 ]
Dakka, A. [1 ]
Gabbeta, V. [1 ]
Pichardo, J. [1 ]
Woll, M. G. [1 ]
Zhang, N. [1 ]
Karp, G. M. [1 ]
Welch, E. M. [1 ]
机构：
[1] PTC Therapeut, South Plainfield, NJ 07080 USA
来源：
NEUROMUSCULAR DISORDERS | 2014年 / 24卷 / 9-10期
关键词：
D O I：
10.1016/j.nmd.2014.06.118
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
G.P.104
引用
收藏
页码：826 / 826
页数：1
相关论文
共 50 条
  • [1] Small molecule compounds that promote exon skipping in the DMD gene
    Naryshkin, N.
    Dakka, A.
    Gabbeta, V.
    Pichardo, J.
    Vazirani, P.
    Ryan, G.
    Woll, M.
    Turpoff, A.
    Zhang, N.
    Zhang, S.
    Karp, G.
    Welch, E.
    NEUROMUSCULAR DISORDERS, 2015, 25 : S261 - S261
  • [2] Prime editing strategies to mediate exon skipping in DMD gene
    Mbakam, Cedric Happi
    Roustant, Jeanne
    Rousseau, Joel
    Yameogo, Pouire
    Lu, Yaoyao
    Bigot, Anne
    Mamchaoui, Kamel
    Mouly, Vincent
    Lamothe, Gabriel
    Tremblay, Jacques P.
    FRONTIERS IN MEDICINE, 2023, 10
  • [3] Antisense oligonucleotide-induced exon skipping of the DMD gene
    Popplewell, Linda
    Dickson, George
    HUMAN GENE THERAPY, 2013, 24 (05) : A21 - A21
  • [4] Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention
    Tyagi, Rahul
    Kumar, Sumit
    Dalal, Ashwin
    Mohammed, Faruq
    Mohanty, Manju
    Kaur, Paramvir
    Anand, Akshay
    CURRENT GENOMICS, 2019, 20 (07) : 519 - 530
  • [5] Clinical safety of eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), in Duchenne muscular dystrophy (DMD) patients amenable to skipping exon 51 of the DMD gene
    Mendell, J.
    Powers, J.
    Duda, P.
    Eliopoulos, H.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S153 - S154
  • [6] Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update
    Omar Sheikh
    Toshifumi Yokota
    Archives of Toxicology, 2022, 96 : 1 - 9
  • [7] Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update
    Sheikh, Omar
    Yokota, Toshifumi
    ARCHIVES OF TOXICOLOGY, 2022, 96 (01) : 1 - 9
  • [8] Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
    Godfrey, C.
    McClorey, G.
    Coursindel, T.
    Betts, C.
    Hammond, S.
    El Andaloussi, S.
    Gait, M.
    Wood, M.
    NEUROMUSCULAR DISORDERS, 2012, 22 : S8 - S8
  • [9] Open-label evaluation of eteplirsen in males with DMD amenable to exon 51 Skipping: PROMOVI
    Koenig, E.
    Shieh, P.
    Abdel-Hamid, H.
    Connolly, A.
    McDonald, C.
    Steiner, D.
    Malhotra, J.
    Khan, N.
    Hu, W.
    Han, B.
    Ciafaloni, E.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S131 - S131
  • [10] PPMO-mediated skipping therapy of duplicated exon 2 in the DMD gene
    Gushchina, L.
    Grounds, K.
    Huang, H.
    Frair, E.
    Schnell, F.
    Hanson, G.
    Simmons, T.
    Wein, N.
    Flanigan, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S89 - S89
12345